rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PACB
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      PacBio to Participate in the Piper Sandler 38th Annual Healthcare Conference
      Nov 17Yahoo FinancePACB
      Here's Why Pacific Biosciences (PACB) Is a Great 'Buy the Bottom' Stock Now
      Nov 16Yahoo FinancePACB
      PacBio (PACB) Stock Sees Split Analyst Revisions As Fair Value Edges Higher
      Nov 16Yahoo FinancePACB
      Pacific Biosciences Stock Q3: Another Revenue Guidance Cut (NASDAQ:PACB)
      Nov 6Seeking AlphaPACB
      Pacific Biosciences of California Inc (PACB) (Q3 2026) Earnings Call Highlights: Revenue Grows ...

      Pacific Biosciences of California Inc (PACB) posted $40.6 million in Q3 2026 revenue, narrowed full-year guidance to $155--$160 million, and reaffirmed a path to cash flow breakeven in 2028.

      Nov 5Yahoo FinancePACB
      Pacific Biosciences of California (PACB) Reports Q3 Loss, Beats Revenue Estimates
      Nov 4Yahoo FinancePACB
      What Pacific Biosciences of California (PACB) Said on Its Q3 Earnings Call
      Nov 4Yahoo FinancePACB
      Pacific Biosciences: Q3 Earnings Snapshot
      Nov 4Yahoo FinancePACB
      Pacific Biosciences Q3 2026 Earnings Call Transcript
      Nov 4BenzingaPACB
      Pacific Biosciences earnings beat by $0.02, revenue topped estimates
      Nov 4Investing.comPACB
      PacBio (NASDAQ:PACB) reports bullish Q3 2026
      Nov 4Yahoo FinancePACB
      Pacific Biosciences of California (PACB) Rises As Market Takes a Dip: Key Facts
      Oct 29Yahoo FinancePACB
      PacBio to Participate in Upcoming Investor Conferences

      MENLO PARK, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing sol...

      Oct 27Business InsiderPACB
      Here's Why You Should Hold PacBio Stock in Your Portfolio for Now
      Oct 27Yahoo FinancePACB
      Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
      Oct 22Yahoo FinancePACB
      Pacific Biosciences of California, Verily Health Agree on Multi-Year Biomedical AI Collaboration
      Oct 19Yahoo FinancePACB
      PacBio and Verily Health form genomic data collaboration
      Oct 19Investing.comPACB
      PacBio and Verily Health Announce Multi-Year Strategic Collaboration to Scale Long-Read Genomics for Biomedical AI
      Oct 19Yahoo FinancePACB
      Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
      Oct 14Yahoo FinancePACB
      PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026
      Oct 14Yahoo FinancePACB
      PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics
      Oct 13Yahoo FinancePACB
      Pacific Biosciences CFO reports $2.05m stock sale
      Oct 10Investing.comPACB
      PacBio (PACB) Stock Gets Fair Value Boost After UBS Starts Coverage Neutral
      Oct 9Yahoo FinancePACBUBS
      Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today

      The latest trading day saw Pacific Biosciences of California (PACB) settling at $2.3, representing a -15.44% change from its previous close.

      Oct 8Yahoo FinancePACB
      Pacific Biosciences of California Insider Sold Shares Worth $2,056,921, According to a Recent SEC Filing
      Oct 8Yahoo FinancePACB
      PacBio Sinks 8% as TychoBio Endorses Its “Highest Quality Biological Data” – the Real Story Is More Complicated

      Key TakeawaysPacBio shares fell 8% after AI drug-discovery company TychoBio said it will use PacBio’s long-read sequencing on more than 10,000 samples. The deal backs PacBio’s pitch to AI companies, but the announcement gave no dollar value.

      Oct 6Yahoo FinancePACB
      PacBio Deepens AI Drug-Discovery Push With TychoBio Deal — PACB Stock Takes A Breather After 103% Rally

      PacBio will generate full-length RNA data from more than 10,000 samples, which TychoBio will use to train AI models to design treatments for rare diseases

      Oct 6Yahoo FinancePACB
      Pacific Biosciences of California, TychoBio Collaborate to Generate Full-Length RNA Data for AI Model Training
      Oct 6Yahoo FinancePACB
      PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics

      PacBio Kinnex sequencing will generate full-length transcript data to help advance TychoBio’s drug discovery modelsMENLO PARK, Calif. and PARIS, Oct. 06, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, and TychoBio, an AI drug discovery company, today announced a collaboration to generate full-length RNA data that TychoBio will use to train models for RNA therapy design. Under the terms of the agreement, TychoBio plans to use PacBio

      Oct 6Yahoo FinancePACB
      Why PacBio (PACB) Stock Is Trading Up Today

      Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 9.9% in the afternoon session after EpiSign Inc. and Geneyx Genomex Ltd. announced a partnership to integrate genomic and epigenomic analysis for rare disease interpretation, incorporating data from PacBio HiFi sequencing.

      Oct 6Yahoo FinancePACB
      Why PacBio (PACB) Stock Is Trading Up Today

      Detailed price information for Pacific Biosciences (PACB-Q) from The Globe and Mail including charting and trades.

      Oct 5The Globe and MailPACB
      Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts

      Pacific Biosciences of California (PACB) concluded the recent trading session at $2.54, signifying a +1.2% move from its prior day's close.

      Oct 2Yahoo FinancePACB
      Pacific Biosciences: Stock Surges As New Use Case Seen - But Caution Is Warranted (PACB)

      Pacific Biosciences of California's business model struggles to gain traction versus larger, profitable competitors like Illumina. Read why PACB stock is a buy.

      Oct 1Seeking AlphaPACB
      Why Is PacBio (PACB) Stock Soaring Today
      Sep 30Yahoo FinancePACB
      Stocks making big moves yesterday: TTM Technologies, PacBio, Nvidia, Palo Alto Networks, and Teleflex

      Detailed price information for Palo Alto Networks (PANW-Q) from The Globe and Mail including charting and trades.

      Sep 29The Globe and MailPACBPANW
      Why PacBio (PACB) Stock Is Trading Up Today

      Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 5.8% in the afternoon session after genomics provider Sampled announced a five-year contract worth up to $27.1 million from the U.S. Department of Veterans Affairs to support research using PacBio Revio sequencing systems.

      Sep 29Yahoo FinancePACB
      Why PacBio (PACB) Stock Is Trading Up Today
      Sep 28BarchartPACB
      Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know

      In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.62, marking a +2.53% move from the previous day.

      Sep 25Yahoo FinancePACB
      1 Stock Under $10 with Exciting Potential and 2 We Avoid

      Detailed price information for RPC Inc (RES-N) from The Globe and Mail including charting and trades.

      Sep 23The Globe and MailPACB
      Pacific Biosciences Targets Clinical Growth, $40M Savings With HiFi Sequencing Push

      Pacific Biosciences of California (NASDAQ:PACB) is maintaining its existing strategy while sharpening execution around clinical genomics, cost controls and the rollout of products designed to improve sequencing economics, Chief Executive Officer Mark Van Oene said during a Morgan Stanley discussion.

      Sep 20Yahoo FinancePACB
      Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today

      In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.38, indicating a +2.99% shift from the previous trading day.

      Sep 17Yahoo FinancePACB
      Analysts Conflicted on These Healthcare Names: Moderna (MRNA), Merck & Company (MRK) and Pacific Biosciences (PACB)

      Detailed price information for Merck & Company (MRK-N) from The Globe and Mail including charting and trades.

      Sep 12The Globe and MailPACB
      Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know

      Pacific Biosciences of California (PACB) closed at $1.27 in the latest trading session, marking a -1.55% move from the prior day.

      Sep 10Yahoo FinancePACB
      Pacific Biosciences (PACB) Has a New Rating from UBS

      Detailed price information for Pacific Biosciences (PACB-Q) from The Globe and Mail including charting and trades.

      Sep 10The Globe and MailPACB
      Q2 Earnings Highlights: PacBio (NASDAQ:PACB) Vs The Rest Of The Life Sciences Tools & Services Stocks

      Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at PacBio (NASDAQ:PACB) and the best and worst performers in the life sciences tools & services industry.

      Sep 8Yahoo FinancePACB
      Pacific Biosciences (PACB) Up 11.6% Since Last Earnings Report: Can It Continue?

      Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Sep 4Yahoo FinancePACB
      PacBio to Participate in the Morgan Stanley 24ᵗʰ Annual Global Healthcare Conference

      MENLO PARK, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 4:50 PM ET in New York, New York. A live webcast of the event can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of the webcast will be ava

      Sep 3Yahoo FinancePACB
      PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test

      PacBio cut its 2026 revenue outlook as weaker instrument demand and a slower SPRQ-Nx transition raised the stakes for clinical adoption.

      Sep 2Yahoo FinancePACB
      Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday - Moderna (NAS

      Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.

      Aug 25BenzingaIMTXMRNAMRVLNYAXPACB

      This is the newest page. Registered accounts read further back.